- Ethos Financial Group LLC discloses a new stake in Viking Therapeutics. A MarketBeat instant alert shows Ethos acquired 10,548 VKTX shares (~$280,000) and recaps recent insider sales over the past 90 days (111,359 shares, ~$3.93M), noting institutional ownership at ~76% and an average analyst target of $87.07. [1]
- Fresh trading levels flagged by Stock Traders Daily. An AI-driven technical note published today outlines near-term support/resistance at $35.40/$37.33, mid‑term at $35.45/$38.60, and long‑term at $25.90/$35.61, with a mixed signal bias. [2]
- Weekend investor analysis keeps VKTX in focus. A Sunday piece syndicated on Yahoo highlights Viking’s progress and near‑term setup as it advances VK2735 across injectable, oral, and maintenance-dosing studies. [3]
Market snapshot
Last close (Fri, Nov 7): $36.77.
Intraday range: $34.69 – $37.50; volume: ~4.65M.
Why VKTX is back on watch this week
1) Fresh institutional interest and ownership trends
Ethos Financial Group’s new position adds to a year when institutions already control roughly three‑quarters of the float. MarketBeat’s automated brief also captures the latest insider activity (including October sales by the CEO and a director), and a blended “Moderate Buy” Street view. While 13F adds don’t guarantee direction, they often increase visibility ahead of catalysts. [4]
2) Technical picture: mixed near‑term, firmer mid‑term
Today’s quant readout pegs $35–$38 as the immediate battleground, with $38.60 a notable mid‑term level to watch into conference week. Traders will look for sustained closes above $37.33–$38.60 to improve momentum; conversely, $35–$35.50 remains the first defense. [5]
3) Clinical and event pipeline: what’s next, precisely
- ObesityWeek® 2025 results (Nov 4–7) – new cardiometabolic data. Viking’s poster showed 78% of prediabetic VK2735 patients shifted to normoglycemia at Week 13 vs 29% on placebo (p=0.0008), and 68% of those with metabolic syndrome were no longer MetS vs 38% on placebo (p=0.02). These findings complement earlier weight‑loss efficacy readouts. [6]
- Maintenance‑dosing study (Phase 1) now enrolling. After an initial 19‑week subcutaneous (SC) induction, participants transition to monthly SC or oral weekly/daily regimens through Week 31 to assess maintenance of weight loss, tolerability, and PK. Top‑line results are expected in 2026. [7]
- VANQUISH Phase 3 program (injectable VK2735) on schedule. Management reiterated in October that enrollment is proceeding well with VANQUISH‑1 (obesity without T2D) aiming to complete enrollment by year‑end 2025 and VANQUISH‑2 (with T2D) in Q1 2026; cash/short‑term investments totaled $715M as of Sept 30, supporting the program’s runway. [8]
- Investor calendar this week.
- Stifel 2025 Healthcare Conference (NYC):Fireside chat Tues, Nov 11, 4:40–5:10 p.m. ET.
- Jefferies Global Healthcare (London):Wed, Nov 19, 8:00–8:25 a.m. GMT (webcast). [9]
Context: the summer selloff and what changed
Back on Aug 19, VKTX shares sold off sharply after mid‑stage results for the oral VK2735 showed ~12% weight loss at 13 weeks but higher discontinuations versus placebo—largely GI events—fueling debate about tolerability for an everyday pill. Since then, investor focus has broadened to the injectable Phase 3 path, maintenance dosing, and the cardiometabolic profile showcased last week. [10]
What it means for investors and readers
- For the week ahead: Watch $38.60 as a mid‑term trigger into the Stifel fireside chat; event headlines often catalyze short‑term moves. [11]
- For the medium term: The story now spans three fronts—injectable Phase 3 efficacy/safety, oral optimization, and maintenance strategies. Fresh data from any of these arms could reframe sentiment. [12]
- For fundamentals: A $715M cash balance and active enrollment cadence underpin the path to 2026 readouts while limiting near‑term financing risk, though dilution is always a sector consideration. [13]
VKTX quick facts (as of Nov 9, 2025)
- Market cap: ~$4.16B; Last close: $36.77.
- Lead asset:VK2735 (dual GLP‑1/GIP agonist) in Phase 3 (SC) and Phase 2 (oral); separate Phase 1 maintenance‑dosing study underway. [14]
- Recent clinical highlight: Significant prediabetes → normoglycemia (78%) and MetS reversal (68%) at Week 13 in VENTURE analysis. [15]
- Upcoming visibility: Stifel (Nov 11–13) and Jefferies London (Nov 17–20; presentation Nov 19). [16]
Editorial note & disclosure
This article aggregates today’s VKTX developments (Nov 9, 2025) and contextualizes them with recently reported data and company disclosures. It is not investment advice. Always do your own research and consider consulting a licensed advisor. Sources: MarketBeat (institutional/insider snapshot), Stock Traders Daily (technical levels), Viking IR (press releases and event timings), and prior coverage from Reuters for historical context. [17]
References
1. www.marketbeat.com, 2. news.stocktradersdaily.com, 3. finance.yahoo.com, 4. www.marketbeat.com, 5. news.stocktradersdaily.com, 6. www.prnewswire.com, 7. ir.vikingtherapeutics.com, 8. ir.vikingtherapeutics.com, 9. ir.vikingtherapeutics.com, 10. www.reuters.com, 11. news.stocktradersdaily.com, 12. ir.vikingtherapeutics.com, 13. ir.vikingtherapeutics.com, 14. ir.vikingtherapeutics.com, 15. www.prnewswire.com, 16. ir.vikingtherapeutics.com, 17. www.marketbeat.com
